A $2.3 trillion spending bill passed by the US Congress yesterday, December 21 includes a proposed change to the laws concerning biologic drugs.
The US Court of Appeals for the Federal Circuit yesterday, December 21, upheld Eli Lilly’s success in barring the sale of a copycat version of cancer treatment Alimta (pemetrexed disodium).
The US International Trade Commission has sided in favour of AbbVie/Allergan, which argued that a rival should be prevented from importing a low-cost version of its Botox treatment into the US for 21 months, because it had stolen trade secrets.
The UK is facing a divergence in supplementary protection certificate regulations across the Irish Sea post-Brexit.
Eli Lilly is expanding its genetics business with the $880 million purchase of Prevail Therapeutics, in a deal that could rise to more than $1 billion.
Medical device company Nevro has agreed to drop a patent infringement suit which accused Boston Scientific of infringing patents related to spinal cord stimulation (SCS) therapy.
A California judge has allowed a patent attorney to proceed with his claims against Allergan which allege the pharmaceutical company fraudulently obtained patents to monopolise pricing.
AstraZeneca has announced it will acquire Boston-based biopharmaceutical company Alexion Pharmaceuticals, in what is potentially the biggest life sciences deal of this year.
Amgen is unlikely to succeed in its bid to revive its patents for the cholesterol drug Repatha, a judge at the US Court of Appeals for the Federal Circuit has told the pharmaceutical company.
Only 10% of essential medicines recommended by the World Health Organisation are on patent, according to a report by research and advocacy organisation, the Geneva Network.